Cambrian BioPharma announced that it has partnered with Aston University and Aston Professor Martin Griffin since 2019 on a startup called Isterian Biotech. According to the announcement, the company’s pipeline features a transglutaminase 2 (TG2) inhibitor that has been shown to reduce lung fibrosis in a mouse model and which Isterian intends to develop as an inhaled therapy for the treatment of idiopathic pulmonary fibrosis (IPF) .
Isterian President and Chairman of the Board, Georg C. Terstappen commented, “Isterian’s strategy of combining rational drug design with efficient multiparametric profiling of synthesized small molecules has been both impressive and highly productive. Notably, for one of our highly potent and selective TG2 inhibitors, we have recently demonstrated efficacy in a mouse model of lung fibrosis for the first time. Using this state-of-the-art approach to drug discovery combined with an impressive team gives us great confidence in the future of this novel company.”
Cambrian BioPharma CEO James Peyer said, “As Cambrian continues on its mission to build medicines that will redefine healthcare in the 21st century, we are very thankful to find brilliant scientists such as Martin and his team that are willing to break the mold. Isterian and its work to reduce fibrosis are a perfect fit alongside the other pipeline companies our team has announced in 2022.”
Read the Cambrian BioPharma press release.
